Department of Error (DOI:10.1016/S0140-6736(09)61375-1);Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

The Lancet

Volumn 374, Issue 9701, 2009, Pages 1606-1616

  Astrup, Arne ^a   Rössner, Stephan ^b   Van Gaal, Luc ^c   Rissanen, Aila ^d   Niskanen, Leo ^e   Al Hakim, Mazin ^f   Madsen, Jesper ^g   Rasmussen, Mads F ^g   Lean, Michael EJ ^h  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e KUOPIO UNIVERSITY HOSPITAL   (Finland)

^f EB FlevoResearch ^*  (Netherlands)

^g NOVO NORDISK A S   (Denmark)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LIRAGLUTIDE; PLACEBO; TETRAHYDROLIPSTATIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROENTERITIS; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL DISORDER; OBESITY; ONLINE SYSTEM; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINGLE DRUG DOSE; SKIN DISEASE; TELECONSULTATION; VOMITING; WEIGHT CHANGE; WEIGHT REDUCTION;

ANALYSIS OF VARIANCE; ANTI-OBESITY AGENTS; BODY MASS INDEX; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EUROPE; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INJECTIONS, SUBCUTANEOUS; LACTONES; LOGISTIC MODELS; MALE; OBESITY; PREDIABETIC STATE; SAFETY; TREATMENT OUTCOME; WAIST CIRCUMFERENCE; WEIGHT LOSS;

EID: 70350619609     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60441-2     Document Type: Erratum

References (46)

1. Berghofer A., Pischon T., Reinhold T., Apovian C.M., Sharma A.M., and Willich S.N. Obesity prevalence from a European perspective: a systematic review. BMC Public Health 8 (2008) 200
2. James P.T., Rigby N., Leach R., and International Obesity Task Force. The obesity epidemic, metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prev Rehabil 11 (2004) 3-8
3. York D.A., Rossner S., Caterson I., et al. Prevention conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: Group I: worldwide demographics of obesity. Circulation 110 (2004) e463-e470
4. Van Gaal L.F., Mertens I.L., and De Block C.E. Mechanisms linking obesity with cardiovascular disease. Nature 444 (2006) 875-880
5. Mackay J., and Mensah G. Atlas of heart disease and stroke (2004), World Health Organization, Geneva
6. Kaukua J., Pekkarinen T., Sane T., and Mustajoki P. Health-related quality of life in obese outpatients losing weight with very-low-energy diet and behaviour modification: a 2-y follow-up study. Int J Obes Relat Metab Disord 27 (2003) 1072-1080
7. Hassan M.K., Joshi A.V., Madhavan S.S., and Amonkar M.M. Obesity and health-related quality of life: a cross-sectional analysis of the US population. Int J Obes Relat Metab Disord 27 (2003) 1227-1232
8. Agerso H., Jensen L.B., Elbrond B., Rolan P., and Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 45 (2002) 195-202
9. Degn K.B., Juhl C.B., Sturis J., et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 53 (2004) 1187-1194
10. Garber A., Henry R., Ratner R., et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373 (2009) 473-481
11. Vilsboll T., Zdravkovic M., Le-Thi T., et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 30 (2007) 1608-1610
12. Madsbad S., Schmitz O., Ranstam J., Jakobsen G., and Matthews D.R. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 27 (2004) 1335-1342
13. Nauck M., Frid A., Hermansen K., et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 32 (2009) 84-90
14. Madsbad S. Liraglutide effect and action in diabetes (LEAD) trial. Expert Rev Endocrinol Metab 4 (2009) 119-129
15. Pi-Sunyer F.X. The effects of pharmacologic agents for type 2 diabetes mellitus on body weight. Postgrad Med 120 (2008) 5-17
16. Buse J.B., Rosenstock J., Sesti G., et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374 (2009) 39-47
17. Vilsboll T., Brock B., Perrild H., et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus. Diabet Med 25 (2008) 152-156
18. Mari A., Degn K., Brock B., Rungby J., Ferrannini E., and Schmitz O. Effects of the long-acting human GLP-1 analogue liraglutide on beta-cell function in normal living conditions. Diabetes Care 30 (2007) 2032-2033
19. Flint A., Raben A., Astrup A., and Holst J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101 (1998) 515-520
20. Verdich C., Flint A., Gutzwiller J.P., et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86 (2001) 4382-4389
21. Naslund E., Barkeling B., King N., et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 23 (1999) 304-311
22. Toft-Nielsen M.B., Madsbad S., and Holst J.J. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22 (1999) 1137-1143
23. Gutzwiller J.P., Drewe J., Goke B., et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 276 (1999) R1541-R1544
24. Zander M., Madsbad S., Madsen J.L., and Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359 (2002) 824-830
25. Willms B., Werner J., Holst J.J., Orskov C., Creutzfeldt W., and Nauck M.A. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81 (1996) 327-332
26. Flint A., Raben A., Ersboll A.K., Holst J.J., and Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes 25 (2001) 781-792
27. Raun K., Von-Voss P., and Knudsen L.B. Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs. Obesity 15 (2007) 1710-1716
28. Raun K., Von-Voss P., Gotfredsen C.F., Golozoubova V., Rolin B., and Knudsen L.B. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 56 (2007) 8-15
29. Larsen P.J., Fledelius C., Knudsen L.B., and Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 50 (2001) 2530-2539
30. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 284 (2000) 3043-3045
31. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. Good Clinical Practice. http://www.ich.org/LOB/media/MEDIA482.pdf (accessed Aug 21, 2009).
32. Lean M.E., and James W.P. Prescription of diabetic diets in the 1980s. Lancet 1 (1986) 723-725
33. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
34. Kolotkin R.L., Crosby R.D., Kosloski K.D., and Williams G.R. Development of a brief measure to assess quality of life in obesity. Obes Res 9 (2001) 102-111
35. Pickering T.G., Hall J.E., Appel L.J., et al. Recommendations for blood pressure measurement in humans and experimental animals. Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 45 (2005) 142-161
36. The seventh report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute. JAMA 289 (2003) 2560-2572
37. National Cholesterol Education Program. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
38. Genuth S., Alberti K.G., Bennett P., et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26 (2003) 3160-3167
39. Li Z., Maglione M., Tu W., et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 142 (2005) 532-546
40. Goldstein D.J. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 16 (1992) 397-415
41. Van-Gaal L.F., Wauters M.A., and De-Leeuw I.H. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord 21 suppl 1 (1997) S5-S9
42. Padwal R.S., and Majumdar S.R. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 369 (2007) 71-77
43. Zelissen P.M.J., Stenlof K., Lean M., et al. Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial. Diab Obesity Metabol 7 (2005) 755-761
44. Courreges J.P., Vilsbøll T., Zdravkovic M., et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabet Med 25 (2008) 1125-1131
45. Harder H., Nielsen L., Tu D.T., and Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 27 (2004) 1915-1921
46. Garber A., Henry R., Ratner M., Hale P., Chang C.T., and Bode B. Monotherapy with liraglutide, a once-daily human GLP-1 analog, provides sustained reductions in A1c, FPG, and weight compared with glimepiride in type 2 diabetes: LEAD-3 mono 2-year results. Diabetes 58 suppl 1 (2009) A42-A43